Compound ID | 148

Update compound information

Meropenem + Vaborbactam

Synonym(s): RPX7009 + meropenem  |  Vabomere/ Carbavance

Class: Beta-lactam (carbapenem) + beta-lactamase inhibitor (heterocyclic boron)

Spectrum of activity: Gram-negative
Details of activity: Complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia/ ventilator-associated bacterial pneumonia, febrile neutropenia, bacteremia, acute pyelonephritis (some indications specifically target infections caused by carbapenem- resistant Enterobacteriaceae )
Combined with other compounds: Yes
Institute where first reported: Rempex Pharmaceuticals (wholly owned subsidiary of The Medicines Co.), USA
Year first mentioned: 2013
Highest developmental phase: Approved by FDA in 2017
Development status: Approved
External links:
Guide to Pharmacology: vaborbactam
Main Source: http://www.vabomere.com
Citations:
  • https://aac.asm.org/content/62/1/e01904-17
  • https://journals.sagepub.com/doi/abs/10.1177/1060028018763288?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=aopd

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us.

    Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.